Mycosis Fungoides: A Case Report

Mehrdad Payandeh¹, Noorodin Karami² and Afshin Karami^3,

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Department of Genetic, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

³Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Cite this paper:
Mehrdad Payandeh, Noorodin Karami and Afshin Karami. Mycosis Fungoides: A Case Report. American Journal of Cancer Prevention. 2017; 5(3):35-36. doi: 10.12691/ajcp-5-3-2

Abstract

First, the term Cutaneous T-cell lymphoma (CTCL) was used by Edelson to describe Mycosis Fungoides (MF) and Sézary Syndrome (SS), which are lymphoproliferative disorders. The most frequent subtype is MF that the exact etiology of the disease is unclear and there is a therapeutic challenge in treating these patients. In this study, we report the patients who initially were treated with combination chemotherapy regimens, but after a while, due to their resistance to these drugs, their treatment was changed and now, their condition is relatively favorable. Therefore, we suggest that further investigations on the prognostic factors associated with this disease are needed that are crucial in terms of response to therapy in these patients.

Keywords:
Cutaneous T-cell lymphoma CTCL Mycosis Fungoides

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Bishop BE, Wulkan A, Kerdel F, El-Shabrawi-Caelen L, Tosti A. Nail Alterations in Cutaneous T-Cell Lymphoma: A Case Series and Review of Nail Manifestations. Skin appendage disorders. 2015; 1(2): 82-6.
[2]	Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Research. 2016; 5.
[3]	Mao X, Lillington DM, Czepulkowski B, Russell‐Jones R, Young BD, Whittaker S. Molecular cytogenetic characterization of Sezary syndrome. Genes, Chromosomes and Cancer. 2003; 36(3): 250-60.
[4]	Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. New England Journal of Medicine. 2004; 350(19): 1978-88.
[5]	Slodownik D, Moshe S, Sprecher E, Goldberg I. Occupational mycosis fungoides–a case series. International Journal of Dermatology. 2017.
[6]	Akinbami AA, Osikomaiya BI, John-Olabode SO, Adediran AA, Osinaike O, Uche EI, et al. Mycosis fungoides: case report and literature review. Clinical medicine insights Case reports. 2014; 7: 95-8.
[7]	Olsen EA. Evaluation, diagnosis, and staging of cutaneous lymphoma. Dermatologic clinics. 2015; 33(4): 643-54.
[8]	Liu K-L, Shen J-L, Yang C-S, Chen Y-J. Mycosis fungoides in a referral center in central Taiwan: A retrospective case series and literature review. Dermatologica Sinica. 2014; 32(3): 148-53.
[9]	Thestrup-Pedersen K, Kaltoft K. Genotraumatic T cells and cutaneous T-cell lymphoma. A causal relationship? Archives of dermatological research. 1994; 287(1): 97-101.
[10]	Kuzel T, Roenigk Jr H, Rosen S. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy. Journal of clinical oncology. 1991; 9(7): 1298-313.
[11]	Keehn CA, Belongie IP, Shistik G, Fenske NA, Glass LF. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007; 14(2): 102.
[12]	Chung CG, Poligone B. Cutaneous T cell lymphoma: an update on pathogenesis and systemic therapy. Current hematologic malignancy reports. 2015; 10(4): 468-76.
[13]	Spencer A, Gazzani P, Gadvi R, Hughes S, Stevens A, Shah F, et al. Computed Tomography scanning in mycosis fungoides–optimising the balance between benefit and harm. British Journal of Dermatology. 2017.
[14]	Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009; 114(20): 4337-53.
[15]	Devata S, Wilcox RA. Cutaneous T-cell lymphoma: a review with a focus on targeted agents. American journal of clinical dermatology. 2016; 17(3): 225-37.
[16]	Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn Jr PA, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. JNCI: Journal of the National Cancer Institute. 1990; 82(3): 203-7.